Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice

被引：0
作者：
I. Blancas
M. Fontanillas
V. Conde
J. Lao
E. Martínez
M. J. Sotelo
A. Jaen
J. L. Bayo
F. Carabantes
J. J. Illarramendi
M. M. Gordon
J. Cruz
A. García-Palomo
C. Mendiola
E. Pérez-Ruiz
J. S. Bofill
J. M. Baena-Cañada
N. M. Jáñez
G. Esquerdo
M. Ruiz-Borrego
机构：
[1] Hospital Universitario Clínico San Cecilio,
[2] Complejo Hospitalario Universitario,undefined
[3] Hospital Clinic de Barcelona,undefined
[4] Hospital Universitario Virgen de las Nieves,undefined
[5] Hospital Universitario Miguel Servet,undefined
[6] Hospital Provincial de Castellón,undefined
[7] Hospital Universitario Clínico San Carlos,undefined
[8] Hospital de Jaén,undefined
[9] Hospital Juan Ramón Jiménez,undefined
[10] Ronda Exterior Norte s/n,undefined
[11] Hospital Universitario Carlos Haya,undefined
[12] Complejo Universitario Hospital de Navarra,undefined
[13] Hospital de Jerez,undefined
[14] Hospital Universitario de Canarias,undefined
[15] Complejo Universitario Asistencial de León,undefined
[16] Hospital Universitario,undefined
[17] Hospital Costa del Sol,undefined
[18] Hospital Nuestra Señora De Valme,undefined
[19] Hospital Universitario Puerta del Mar,undefined
[20] Hospital Ramón y Cajal,undefined
[21] Clínica Benidorm,undefined
[22] Hospital Universitario Virgen del Rocío,undefined
来源：
Clinical and Translational Oncology | 2018年 / 20卷
关键词：
Metastatic breast cancer; Postmenopausal women; Hormone receptor-positive advanced breast cancer; Fulvestrant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：862 / 869
页数：7
相关论文
共 148 条
[1]  
Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
[2]  
Bray F(2016)The global decrease in cancer mortality: trends and disparities Ann Oncol 27 926-933
[3]  
Siegel RL(2007)Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Breast Cancer Res 9 R6-1887
[4]  
Ferlay J(2010)Aromatase inhibitors: prediction of response and nature of resistance Expert Opin Pharmacother 11 1873-784
[5]  
Lortet-Tieulent J(2007)Fulvestrant (Faslodex)—how to make a good drug better Oncologist 12 774-3403
[6]  
Jemal A(2002)Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396-3395
[7]  
Hashim D(2002)Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 3386-1613
[8]  
Boffetta P(2004)Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 1605-4600
[9]  
La Vecchia C(2010)Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer J Clin Oncol 28 4594-4535
[10]  
Rota M(2014)Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial J Natl Cancer Inst 106 djt337-511
12345678910